The purpose of this clinical study is to learn more about the safety and effectiveness of an experimental drug for the treatment of peanut allergy (PVX108) in children aged 4 to 11 years and adolescents (aged 12 to 17 years) with peanut allergy. We want to compare dose levels of the study drug in children aged 4 to 11 years. We want to see if the study drug is safe and reduces peanut allergy in younger children.
-Physical exam and vital signs -Blood and urine sample collection -Allergy skin testing -Oral Food Challenge Test -Injection of study medication monthly -Phone calls after the injection days to check on child
Information provided upon request, Parking Vouchers
Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
Edwin Kim
Pediatrics - Allergy Immunology and Rheumatology
Clinical or Medical
Interventional
Allergy
23-2178
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
